Substituted Tricyclic Compounds, Pharmaceutical formulation which comprises,Use of said Compound for producing a Medicament used to selectively inhibit sPLA2 and alleviate Pathological effects of related diseases

摘要

It describes new tricyclic compounds and the use of these compounds to inhibit the release of sPLA2 induced fatty acids into treatments for diseases such as septic shock. These compounds have formula (I),Where Z is cyclohexane or phenyl, R20 is selected as a group (a),(b) And (c),Among them: (a) C 5-20, alquenilo C5-20, c-5-20 tar, c-5-20, c-thyroid or heterocyclic excimer, or (b) a member of group a replaced by one or more non interfering substitutes independently selected; or (c) a single condition group composed of 1 to 12 carbon atoms, 1. Hydrogen, oxygen, nitrogen and sulfur; select delgroup atomic combination composed of (I) carbon and hydrogen (II) sulfur (III) monooxygen (I V) one or two nitrogen and hydrogen (V) carbon, hydrogen and sulfur (VI) one carbon, hydrogen and oxygen;R80 is a group of R80 selected from (a) or (b);R21 is a non-interference substitute selected from the group consisting of - oh y-o (CH2) Tr5, wherein R5 is h, - CN, - NH2, - CONH2, - conr9r10, - nhso2r15, - conhs2r15, r15-c1-6 or - CF3, substituted by - CO2H or - co2-c1-4; and (ya) group;It is a single acid group composed of 1-7 and t-1-5 acid linkers; R3 consists of non interfering substitutes, carbon thyroid radicals, and carbon thyroid substitutes, Aperiodic and aperiodic radicals are replaced by noise substitutes; or their racemates, solutions, polymers, optically isomerized isomers, disordered derivatives or salts acceptable to drugs.